LERIGLITAZONE FOR TREATING LUNG INFLAMMATION AND INTERSTITIAL LUNG DISEASE
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jun 8, 2023
app pub date -
Apr 30, 2021
filing date -
Apr 30, 2020
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present disclosure provides methods of treating viral-induced inflammatory lung conditions or diseases, acute inflammation of the lung, or interstitial lung disease with 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione, or a pharmaceutically acceptable salt thereof, or 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione, or a pharmaceutically acceptable salt thereof.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully